Blockchain Registration Transaction Record

VolitionRx Launches €6.3M DETECSEPS Project for Early Sepsis Detection

VolitionRx launches DETECSEPS project with €6.3M French funding to detect sepsis early using Nu.Q NETs biomarker and IDS France analyzer.

Sepsis is a life-threatening condition that affects millions worldwide and requires rapid intervention. The DETECSEPS project could lead to a faster, more accurate way to identify patients at risk of progressing to sepsis, enabling earlier treatment and potentially saving lives. For VolitionRx, this represents a significant opportunity to validate its Nu.Q NETs biomarker in a major clinical setting and tap into a multibillion-dollar market. If successful, the project could establish a new standard of care for sepsis detection, benefiting patients, healthcare providers, and investors alike.